Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margaret House

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Trials (London, England)|April 9, 2024
Accrual Quality Improvement Program for clinical trialsEllen Richmond, Goli Samimi, Margaret House, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|July 11, 2023
Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3Nerlyne Desravines, Chiu-Hsieh Hsu, Sopan Mohnot, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 3, 2022
Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study DesignsGoli Samimi, Margaret House, Kelly Benante, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomyJason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 27, 2024
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer SurgeryTracy M Downs, Howard H Bailey, Taja Lozar, et al.
European Urology Focus|December 14, 2022
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active SurveillanceJ Kellogg Parsons, Peter A Pinto, Christian P Pavlovich, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|April 9, 2024
Accrual Quality Improvement Program for clinical trialsEllen Richmond, Goli Samimi, Margaret House, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|July 11, 2023
Feasibility of 5-fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3Nerlyne Desravines, Chiu-Hsieh Hsu, Sopan Mohnot, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 3, 2022
Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study DesignsGoli Samimi, Margaret House, Kelly Benante, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|August 28, 2015
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomyJason R Gee, Daniel R Saltzstein, Edward Messing, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 24, 2022
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-OophorectomyMeghna S Trivedi, Nadir Arber, Eitan Friedman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|August 27, 2024
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer SurgeryTracy M Downs, Howard H Bailey, Taja Lozar, et al.
European Urology Focus|December 14, 2022
A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active SurveillanceJ Kellogg Parsons, Peter A Pinto, Christian P Pavlovich, et al.
Pageof 1